glutazumab (GMA102) / Gmax Biopharm - LARVOL DELTA

Warfarin Exposure Leads to Loss of Binding of Emicizumab to Factor IX (ASH 2024) - "We recombined the FIX-TM transgene into a doxycycline-inducible, genomically-integrated landing pad in HEK293 Freestyle cells...We tested antibody binding to displayed FIX under all conditions to assess the expression of FIX, carboxylation of the FIX Gla domain, and emicizumab-FIX binding by incubating cells with monoclonal antibodies to FIX light chain (GMA-124), heavy chain (GMA-102), carboxylated FIX Gla domain (GMA-001), and emicizumab at at concentrations ranging from 0.15-1.5 mg/mL...This finding offers new insights into the interaction of emicizumab with FIX that would not be able to be detected with conventional FIX activity assays. Additionally, this work suggests there is the potential for reduced efficacy if emicizumab were to be used clinically in settings of perturbed vitamin K metabolism."

Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases